Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix |
| |
Authors: | AP Kudelka CF Verschraegen T Levy CL Edwards A Fishman RS Freedman A Kaplan DG Kieback R Mante K Ende M Steger JJ Kavanagh |
| |
Affiliation: | University of Texas MD Anderson Cancer Center, Section of Gynecologic Medical Oncology, Houston 77030-4095, USA. |
| |
Abstract: | Eighteen patients with squamous cell cancer of the cervix were treated with i.v. docetaxel 100 mg/m2 over 1 h every 21 days. No patient received prior chemotherapy, except as a radiation sensitizer. Median age was 42 years (range 30-58) and Zubrod performance status was 1 (0-2). Ten (59%) patients had prior surgery and 11 (65%) had prior radiation therapy. Sixteen patients were evaluable for response. Two patients had a partial response (13%; 95% CI 0-32%) and eight (50%; 95% CI 23-77%) had stable disease. Dose reduction to 75 mg/m2 was required in 10 patients and to 55 mg/m2 in one patient. Granulocytopenia was the major hematopoietic toxicity (31% grade 3 and 44% grade 4). Docetaxel is active in patients with squamous cell cancer of the cervix and may be tolerable at this dose schedule. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |